<DOC>
	<DOCNO>NCT01980953</DOCNO>
	<brief_summary>This 4-part study assess effect formulation , food , active pharmaceutical ingredient ( API ) lot pharmacokinetics GDC-0032 healthy volunteer . Part 1 open-label , 3-period , 6-sequence study , Parts 2 , 3 , 4 open-label 2-period crossover study . Participants receive single dos GDC-0032 capsule tablet formulation , fast fed state .</brief_summary>
	<brief_title>A Study Evaluate Effect Particle Size , Formulation Food Pharmacokinetics GDC-0032 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Males female nonchildbearing potential , 18 55 year age , inclusive ; female meet follow criterion : nonpregnant , nonlactating , either postmenopausal least 1 year surgically sterile least 90 day . Body mass index ( BMI ) 18.5 32 kg/m^2 , inclusive In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign clinical laboratory evaluation Negative test select drug abuse Screening ( include alcohol ) Checkin ( Day 1 ; include alcohol ) Negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] antihepatitis C virus [ HCV ] ) negative human immunodeficiency virus ( HIV ) antibody screen Males either sterile agree use approve method contraception define protocol Period 1 Checkin ( Period 1 , Day 1 ) 90 day follow last dose study drug Significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug , except appendectomy , hernia repair , and/or cholecystectomy History alcoholism drug addiction within 1 year prior Period 1 Checkin ( Period 1 , Day 1 ) Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis History Type 1 2 diabetes mellitus and/or elevate fast glucose ( great [ &gt; ] 120 milligram per deciliter [ mg/dL ] ) baseline ( confirmed repeat ) History Gilbert 's Syndrome Evidence malabsorption syndrome condition would interfere enteral absorption Inability unwillingness swallow pill consume highfat breakfast Use tobacco nicotinecontaining product within 6 month prior Period 1 Checkin ( Period 1 , Day 1 ) entire study Participation investigational study drug trial receipt investigational study drug occur within 5 halflives 30 day , whichever longer , prior Period 1 Checkin ( Period 1 , Day 1 ) entire study duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>